Assessment of the therapeutic effect of oral propranolol on retinochoroidal hemangioma

Assessment of the therapeutic effect of oral propranolol on retinochoroidal hemangioma - Oral propranolol therapy for retinochoroidal hemangioma

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006623

Enrollment

Registered

2011-11-01

Start date

2011-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

retinochoroidal hemangioma

Interventions

oral propranolol therapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients with visual impairment due to retinochoroidal hemangioma

Exclusion criteria

Exclusion criteria: patients ineligible for oral propranolol therapy or considered ineligible for this clinical trial by investigators

Design outcomes

Primary

Measure	Time frame
visual acuity, size of retinochoroidal hemangioma	—

Countries

Japan

Contacts

Public ContactHirotaka Tanabe

National Hospital Organization Nagoya Medical Center Ophthalmology

tennsyoudragon@yahoo.co.jp052-951-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026